论文部分内容阅读
目的 :检测PARP14在胰腺癌中的表达及意义,并探讨其对胰腺癌细胞生物学功能的影响。方法 :利用人类肿瘤相关的基因表达汇编(gene expression omnibus,GEO)和癌症基因组图谱(the cancer genome atlas,TCGA)中的胰腺癌基因表达谱数据,分析PARP14在胰腺癌及癌旁中的表达差异,并进一步通过TCGA数据库分析PARP14表达量与总体生存期和无病生存期的关系(Kaplan-Meier法和Log-rank检验)。在人胰腺癌细胞株BXPC-3和CFPAC-1中干扰PARP14后,分别通过CCK8增殖实验和集落形成实验检测其对胰腺癌细胞增殖能力的影响。结果:GEO数据显示PARP14在胰腺癌组织中的表达显著高于其在癌旁组织中的表达,差异具有统计学意义(P<0.001)。TCGA数据表明胰腺癌中高表达PARP14组患者的总体生存期显著低于低表达组的患者(P<0.05)。体外实验表明,干扰PARP14后,胰腺癌细胞增殖能力明显降低(P<0.05)。结论:PARP14在胰腺癌中高表达并与预后负相关,且其高表达与胰腺癌细胞增殖能力相关,PARP14可能成为胰腺癌预后预测及治疗的靶点。
Objective: To detect the expression of PARP14 in pancreatic cancer and its significance, and to explore its biological function of pancreatic cancer cells. Methods: The expression of PARP14 in pancreatic cancer and paracancerous tissues was analyzed by gene expression profiling data of human tumor-associated gene expression omnibus (GEO) and the cancer genome atlas (TCGA) , And further analyzed the relationship between PARP14 expression and overall survival and disease-free survival by the TCGA database (Kaplan-Meier method and Log-rank test). After interfering with PARP14 in human pancreatic cancer cell lines BXPC-3 and CFPAC-1, the effects of PARP14 on the proliferation of pancreatic cancer cells were tested by CCK8 proliferation assay and colony formation assay, respectively. Results: The data of GEO showed that the expression of PARP14 in pancreatic cancer tissues was significantly higher than that in paracancerous tissues, the difference was statistically significant (P <0.001). TCGA data showed that the overall survival of patients with high expression of PARP14 in pancreatic cancer was significantly lower than that in patients with low expression (P <0.05). In vitro experiments show that, after interference PARP14, the proliferation of pancreatic cancer cells was significantly reduced (P <0.05). CONCLUSIONS: PARP14 is highly expressed in pancreatic cancer and negatively correlated with prognosis. The high expression of PARP14 is correlated with the proliferation of pancreatic cancer cells. PARP14 may be the target of prognosis and treatment of pancreatic cancer.